|
 |
|
|||||||
|
|||||||||
© 2004 by the American Diabetes Association, Inc.
Letters: Observations |
Similar A1C Outcomes in Type 1 Diabetic Patients Undergoing Intensive Diabetes Management With Preprandial Rapid-Acting Insulin and Either CSII or Glargine
From the Department of Endocrinology, University of Southern California, Los Angeles, California
Address correspondence to Dr. Anne Harmel, Endocrinology, University of Southern California, 2905 Alma Ave., Manhattan Beach, CA 90266. E-mail: momofmax{at}hotmail.com
The importance of achieving and maintaining tight glycemic control in patients with type 1 diabetes is well known (1). Continuous insulin infusion therapy (CSII) has been available for many years, but only recently have reports of efficacy with rapid-acting insulin analogues been published. Similarly, multiple daily injection (MDI) therapy using glargine insulin in conjunction with premeal rapid-acting insulin is relatively new (2).
In our diabetes center, all patients with type 1 diabetes receive the same diabetes education, including instruction in carbohydrate counting. All patients are given the option of either CSII or MDI therapy and are encouraged to use whichever treatment maintains their blood glucose levels as close to normal as possible.
To assess our quality of care, we performed a random chart audit of 150 patients. To be included in the analysis, patients had to have type 1 diabetes and be treated for at least 6 months with either CSII using rapid-acting insulin (lispro or aspart) or MDI with insulin glargine with premeal rapid-acting insulin. Patients who were pregnant, <15 years of age, or referred for treatment of severe recurrent hypoglycemia were excluded.
There were 103 patients who met our criteria; 58 were on CSII and 45 were on MDI therapy. Glargine was given in the morning in 11%, in the evening in 60%, and twice a day in 29% of patients. Age, duration of diabetes, and incidence of complications were similar in both groups. Duration of therapy was 16.0 ± 5.8 (means ± SD) (CSII) vs. 11.6 ± 3.8 months (MDI) (P < 0.0001). Most recent A1C levels were the same in both groups—6.79 ± 1.07 (CSII) vs. 6.84 ± 0.90% (MDI) (P = 0.82). One patient in the CSII group and two patients in the MDI group had an episode of severe hypoglycemia. One patient in the CSII group had two episodes of diabetic ketoacidosis.
Therefore, both CSII and MDI therapy can be used to treat patients with type 1 diabetes to target. Prospective data are needed to confirm the findings of this cross-sectional analysis.
Footnotes
A.P.H. has received honoraria from and served on advisory boards for NovoNordisk, Aventis, and Lilly and has received research support from Minimed and Aventis. R.M. is a member of the Aventis speaker bureau.
References
- The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329:977–986, 1993
[Abstract/Free Full Text]
- DeWitt DE, Hirsch IB: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 289:2254–2264, 2003
[Abstract/Free Full Text]
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Zirlik, S. M. Abdullah, N. Gerdes, L. MacFarlane, U. Schonbeck, A. Khera, D. K. McGuire, G. L. Vega, S. Grundy, P. Libby, et al. Interleukin-18, the Metabolic Syndrome, and Subclinical Atherosclerosis: Results From the Dallas Heart Study Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 2043 - 2049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ruotsalainen, U. Salmenniemi, I. Vauhkonen, J. Pihlajamaki, K. Punnonen, S. Kainulainen, and M. Laakso Changes in Inflammatory Cytokines Are Related to Impaired Glucose Tolerance in Offspring of Type 2 Diabetic Subjects Diabetes Care, December 1, 2006; 29(12): 2714 - 2720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yates, A. Hasnat Milton, K. Dear, and G. Ambler Continuous Glucose Monitoring-Guided Insulin Adjustment in Children and Adolescents on Near-Physiological Insulin Regimens: A randomized controlled trial Diabetes Care, July 1, 2006; 29(7): 1512 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Schade and V. Valentine Counterpoint: Are Insulin Pumps Underutilized in Type 1 Diabetes? No. Diabetes Care, June 1, 2006; 29(6): 1453 - 1455. [Full Text] [PDF]
|
|
|
|
|
|
A. Nakamura, K. Shikata, M. Hiramatsu, T. Nakatou, T. Kitamura, J. Wada, T. Itoshima, and H. Makino Serum Interleukin-18 Levels Are Associated With Nephropathy and Atherosclerosis in Japanese Patients With Type 2 Diabetes Diabetes Care, December 1, 2005; 28(12): 2890 - 2895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Wilson, B. A. Buckingham, E. L. Kunselman, M. M. Sullivan, H. U. Paguntalan, and S. E. Gitelman A Two-Center Randomized Controlled Feasibility Trial of Insulin Pump Therapy in Young Children With Diabetes Diabetes Care, January 1, 2005; 28(1): 15 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Retnakaran, J. Hochman, J. H. DeVries, H. Hanaire-Broutin, R. J. Heine, V. Melki, and B. Zinman Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections: The impact of baseline A1c Diabetes Care, November 1, 2004; 27(11): 2590 - 2596. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |